{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Raloxifene",
    "query": {
      "intervention": "Raloxifene"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 45,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Raloxifene&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T21:02:40.391Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03623633",
      "title": "Comparative Antiresorptive Efficacy Discontinuation of Denosumab",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Osteoporosis, Postmenopausal",
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "denosumab",
          "type": "DRUG"
        },
        {
          "name": "alendronate",
          "type": "DRUG"
        },
        {
          "name": "raloxifene",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "45 Years and older · Female only"
      },
      "enrollment_count": 51,
      "start_date": "2018-11-30",
      "completion_date": "2023-08-01",
      "has_results": false,
      "last_update_posted_date": "2023-06-07",
      "last_synced_at": "2026-09-02T21:02:40.391Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03623633"
    },
    {
      "nct_id": "NCT00019500",
      "title": "Raloxifene in Preventing Breast Cancer in Premenopausal Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "raloxifene",
          "type": "DRUG"
        },
        {
          "name": "evaluation of cancer risk factors",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "23 Years",
        "maximum_age": "47 Years",
        "sex": "FEMALE",
        "summary": "23 Years to 47 Years · Female only"
      },
      "enrollment_count": null,
      "start_date": "1998-12",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2013-06-20",
      "last_synced_at": "2026-09-02T21:02:40.391Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00019500"
    },
    {
      "nct_id": "NCT00383422",
      "title": "Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoporosis, Postmenopausal"
      ],
      "interventions": [
        {
          "name": "Arzoxifene",
          "type": "DRUG"
        },
        {
          "name": "Raloxifene",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "50 Years to 75 Years · Female only"
      },
      "enrollment_count": 320,
      "start_date": "2006-10",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2010-01-28",
      "last_synced_at": "2026-09-02T21:02:40.391Z",
      "location_count": 5,
      "location_summary": "Gainesville, Georgia • Urbandale, Iowa • Billings, Montana + 2 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Georgia"
        },
        {
          "city": "Urbandale",
          "state": "Iowa"
        },
        {
          "city": "Billings",
          "state": "Montana"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00383422"
    },
    {
      "nct_id": "NCT00030147",
      "title": "Raloxifene and Rimostil for Perimenopause-Related Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Perimenopausal Depression",
        "Depression"
      ],
      "interventions": [
        {
          "name": "Raloxifene",
          "type": "DRUG"
        },
        {
          "name": "Rimostil",
          "type": "DRUG"
        },
        {
          "name": "Transdermal Estradiol",
          "type": "DRUG"
        },
        {
          "name": "Placebo skin patch and placebo tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 60 Years · Female only"
      },
      "enrollment_count": 65,
      "start_date": "2002-02",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2016-09-05",
      "last_synced_at": "2026-09-02T21:02:40.391Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00030147"
    },
    {
      "nct_id": "NCT00431444",
      "title": "Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "Raloxifene",
          "type": "DRUG"
        },
        {
          "name": "Zoledronic acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral pills",
          "type": "DRUG"
        },
        {
          "name": "Placebo intravenous (i.v.) infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 80 Years · Female only"
      },
      "enrollment_count": 110,
      "start_date": "2007-01",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2011-03-29",
      "last_synced_at": "2026-09-02T21:02:40.391Z",
      "location_count": 17,
      "location_summary": "Phoenix, Arizona • Buena Park, California • Washington D.C., District of Columbia + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Buena Park",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00431444"
    },
    {
      "nct_id": "NCT00001837",
      "title": "Effects of Raloxifene on the Uterus and Ovaries of Premenopausal Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer",
        "Breast Neoplasm"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 60,
      "start_date": "1998-11",
      "completion_date": "2005-10",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-09-02T21:02:40.391Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001837"
    },
    {
      "nct_id": "NCT00079924",
      "title": "Effects of Teriparatide in Postmenopausal Women With Osteoporosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Postmenopausal Osteoporosis"
      ],
      "interventions": [
        {
          "name": "teriparatide",
          "type": "DRUG"
        },
        {
          "name": "aldrenodate",
          "type": "DRUG"
        },
        {
          "name": "raloxifene",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "50 Years and older · Female only"
      },
      "enrollment_count": 200,
      "start_date": "2004-11",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2007-05-25",
      "last_synced_at": "2026-09-02T21:02:40.391Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00079924"
    },
    {
      "nct_id": "NCT00190593",
      "title": "Raloxifene Use for The Heart",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cardiovascular Diseases",
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "raloxifene",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "55 Years and older · Female only"
      },
      "enrollment_count": 10000,
      "start_date": "1998-06",
      "completion_date": "2005-11",
      "has_results": false,
      "last_update_posted_date": "2007-01-26",
      "last_synced_at": "2026-09-02T21:02:40.391Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00190593"
    },
    {
      "nct_id": "NCT01166958",
      "title": "Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window?",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "Teriparatide",
          "type": "DRUG"
        },
        {
          "name": "Raloxifene",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "89 Years",
        "sex": "FEMALE",
        "summary": "60 Years to 89 Years · Female only"
      },
      "enrollment_count": 26,
      "start_date": "2010-09",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2014-09-22",
      "last_synced_at": "2026-09-02T21:02:40.391Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01166958"
    },
    {
      "nct_id": "NCT00670319",
      "title": "Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoporosis, Postmenopausal"
      ],
      "interventions": [
        {
          "name": "Raloxifene HCL",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "Up to 80 Years · Female only"
      },
      "enrollment_count": 7705,
      "start_date": "1994-11",
      "completion_date": "1999-09",
      "has_results": false,
      "last_update_posted_date": "2008-05-01",
      "last_synced_at": "2026-09-02T21:02:40.391Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00670319"
    }
  ]
}